- Report
- May 2024
- 199 Pages
Global
From €3217EUR$3,374USD£2,742GBP
€3574EUR$3,749USD£3,046GBP
- Report
- March 2024
- 181 Pages
Global
From €3217EUR$3,374USD£2,742GBP
€3574EUR$3,749USD£3,046GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,063GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,063GBP
- Report
- May 2024
- 129 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- May 2024
- 134 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- May 2024
- 133 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- May 2024
- 128 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- April 2024
- 138 Pages
Global
From €3717EUR$3,899USD£3,168GBP
- Report
- June 2024
- 193 Pages
Global
From €4719EUR$4,950USD£4,022GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,063GBP
- Report
- February 2024
- 112 Pages
Global
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 140 Pages
Global
From €4528EUR$4,750USD£3,860GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2383EUR$2,500USD£2,031GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2860EUR$3,000USD£2,438GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2860EUR$3,000USD£2,438GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2860EUR$3,000USD£2,438GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1430EUR$1,500USD£1,219GBP
- Report
- November 2022
- 154 Pages
Global
From €4767EUR$5,000USD£4,063GBP
Sunitinib is an oncology drug used to treat a variety of cancers, including gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain proteins that can cause cancer cells to grow and divide. Sunitinib is typically administered orally, and is available in both capsule and tablet form.
Sunitinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2006. It has since become a popular treatment option for many types of cancer, due to its effectiveness and relatively low side effects. Sunitinib is also used in combination with other drugs to treat certain types of cancer, such as advanced renal cell carcinoma.
Some of the companies in the Sunitinib market include Pfizer, Novartis, and AstraZeneca. These companies manufacture and distribute the drug, as well as provide support and resources for patients and healthcare professionals. Show Less Read more